NEW YORK (TheStreet) -- CHANGE IN RATINGS
Autodesk (ADSK) downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.
Adtran (ADTN) upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.
Cummins (CMI) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.Concur (CNQR) downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target. Devon Energy (DVN) downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims. Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook. Exelon (EXC) upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend. FirstMerit (FMER) upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target. Health Net (HNT) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving. Juniper (JNPR) upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending. Linear Technology (LLTC) upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation. Universal Display (PANL) downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility. Parker Hannifin (PH) upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target. Perrigo (PRGO) downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals. PSS World Medical (PSSI) downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV